Mehdi Farishta, MD
Pulmonary Disease · Morgantown, WVNPI 1861914194
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,901 of the $3,990 with a category attached, or 72.7%. 17 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 38.7% of the total. Reporting peaked in 2024 at $1,599 and has fallen 86.4% since, to $217 in 2025.
Across 52 payments — averaging $76.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- GSK$517
- AstraZeneca$395
- Pulmonx Corporation$371
- Insmed, Inc.$236
- Inari Medical, Inc.$179
- plus $750 from 11 others
What the payments were for
- Travel & lodging$92423%
- Food & beverage$2,90173%
- Education$1654%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 14 | $1,543 |
| GSK | 6 | $517 |
| AstraZeneca | 5 | $395 |
| Pulmonx Corporation | 4 | $371 |
| Insmed, Inc. | 4 | $236 |
| Inari Medical, Inc. | 1 | $179 |
| Gilead | 4 | $165 |
| Sanofi | 2 | $131 |
| Grifols USA, LLC | 2 | $113 |
| Boehringer Ingelheim | 1 | $93 |
| Jazz Pharmaceuticals Inc. | 1 | $90 |
| Amgen | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Resmed Corp | 1 | $28 |
| Merck | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$1,347
- CHARTIS CATHETER$268
- ZEPHYR DELIVERY CATHETER$268
- ZEPHYR ENDOBRONCHIAL VALVE$268
- PULMONX CHARTIS TABLET CONSOLE$268
- BREZTRI$250
- NUCALA$247
- FLOWTRIEVER CATHETER, S$179
- CT THROMBECTOMY SYSTEM KIT$179
- TRELEGY ELLIPTA$122
- Veklury$120
- TEZSPIRE$110
- DUPIXENT$108
How this compares
$3,990 in reported general payments places this provider in the 70th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $20,191 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $940 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $517 | $20,19121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Morgantown
- Roger AbrahamsMorgantown$133K
- Peter KochupuraMorgantown$22K
- Sidharth BhasinMorgantown$7K
- Andrzej JaworskiMorgantown$5K
- Kyle ChapmanMorgantown$5K
- Haroon AhmedMorgantown$4K
- Sarah HadiqueMorgantown$4K
- Srinivasa PotlaMorgantown$3K
- Robert StansburyMorgantown$3K
- Joseph RussoMorgantown$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.